Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

(2014) Paul Nyirjesy et al.   CURRENT MEDICAL RESEARCH AND OPINION

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

(2014) M. A. Nauck et al.   DIABETES OBESITY & METABOLISM

Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

(2014) J. Dziuba et al.   DIABETES OBESITY & METABOLISM

Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria

(2014) Suzanne Geerlings et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Urinary Tract Infection in Randomized Phase III Studies of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

(2014) Lindsay E. Nicolle et al.   POSTGRADUATE MEDICINE

A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy

(2014) Michelle Orme et al.   Diabetology & Metabolic Syndrome

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

(2013) Clifford J Bailey et al.   BMC Medicine

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES CARE

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

(2013) C. S. Kovacs et al.   DIABETES OBESITY & METABOLISM

Urinary tract infections in patients with diabetes treated with dapagliflozin

(2013) Kristina M. Johnsson et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

(2013) Kristina M. Johnsson et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Adherence to Therapies in Patients with Type 2 Diabetes

(2013) Luis-Emilio García-Pérez et al.   Diabetes Therapy

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life

(2009) Michael F. Pollack et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Diabetes medications and body weight

(2009) Joanna Mitri et al.   Expert Opinion On Drug Safety

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL

Improving Efficiency of Inferences in Randomized Clinical Trials Using Auxiliary Covariates

(2008) Min Zhang et al.   BIOMETRICS

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

(2008) Wei Meng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: A principled yet flexible approach

(2007) Anastasios A. Tsiatis et al.   STATISTICS IN MEDICINE